<DOC>
	<DOCNO>NCT00903929</DOCNO>
	<brief_summary>Patients undergo total body irradiation ( TBI ) stem cell transplantation prolong period low count specific blood cell call platelet . These low platelet count cause bleed infection . Thus far , drug available use speed recovery platelet , therefore transfusion often necessary . The purpose study test safety drug call eltrombopag patient receive TBI . The investigator want find effect , good bad , people low platelet count due treatment TBI . The investigator also test well eltrombopag may work different dos determine drug speed recovery platelet .</brief_summary>
	<brief_title>Phase I Study Eltrombopag Promoting Thrombopoiesis After Total Body Irradiation</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Acute Radiation Syndrome</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>1 . Age ≥ 18 2 . Able give write informed consent clinical trial 3 . Scheduled undergo autologous allogeneic stem cell transplantation sibling , relate donor , unrelated donor use condition regimen contain least 400 cGy TBI 4 . Transplantation perform one follow medical condition : Acute myelogenous leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia chronic , accelerate , blastic phase Myelodysplastic syndrome Myeloproliferative diseases chronic myelomonocytic leukemia , agnogeneic myeloid metaplasia myelofibrosis , polycythemia vera , essential thrombocythemia Hodgkin 's lymphoma NonHodgkin 's lymphoma Multiple myeloma Chronic lymphocytic leukemia Other malignancy marrow disease aplastic anemia transplant would appropriate approval principal investigator 5 . Patients therapyrelated AML MDS may include prior malignancy remission least 12 month . If remission le 12 month , approval principal investigator require . Entry could allow malignancy control expect relapse e.g . localized prostate cancer treat XRT . 6 . Patients must meet pretransplantation criterion transplant center include acceptable test heart , liver , kidney , lung function ( Standard screen HSCT per PI , coinvestigators ) . 7 . Karnofsky performance status must ≥70 % . 1 . TBI dose less 400 cGY 2 . Cord blood transplantation 3 . HIV infection 4 . Pregnancy breastfeed 5 . Creatinine bilirubin ALT AST great two time upper limit normal , unless abnormal bilirubin due Gilbert 's syndrome 6 . Active infection require systemic antibiotic therapy antibacterial , antifungal , antiviral agent 7 . Concomitant enrollment another therapeutic clinical study except PI approval 8 . Must previously receive eltrombopag 9 . Patients moderate severe liver disease ( ALT , AST , bilirubin ≥ 2X upper limit normal , unless abnormal bilirubin due Gilbert 's syndrome ) exclude 10 . Patients high risk thromboembolism base genetic syndrome , past thromboembolic disease past 6 month exclude study , exception catheter relate clot</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>